From GlobeNewswire: 2025-03-28 08:01:00

Aptose Biosciences is advancing a triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML) in the TUSCANY clinical trial. Tuspetinib shows promise in achieving complete remissions in difficult-to-treat AML patients. The company also signed a debt conversion agreement with Hanmi to support clinical development. No significant safety concerns reported to date.

In 2024, Aptose completed several financings totaling $37 million to develop the TUS-based triplet therapy for AML. The company also signed a loan facility agreement with Hanmi. Additionally, Aptose entered into a CRADA with the National Cancer Institute for the clinical development of TUS in AML and MDS populations. The company met Nasdaq minimum bid compliance.

Financially, Aptose’s net loss decreased to $25.4 million in 2024 from $51.2 million in 2023. The company had $6.7 million in cash, cash equivalents, and restricted cash equivalents as of December 31, 2024. Aptose’s research and development expenses decreased to $15.1 million in 2024, driven by reduced costs in clinical trials and manufacturing activities.

Aptose has completed key milestones, including dosing patients in the TUSCANY trial and signing agreements with Hanmi and the NCI. In 2025, the company plans to report additional data from the triplet therapy trial, execute a collaboration with Hanmi, and present at the EHA2025 Congress. Aptose is focused on developing precision medicines for oncology, starting with hematology.



Read more at GlobeNewswire:: Aptose Reports Year End 2024 Results and Corporate